drugset / Trial / NCT00336674

Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes

NCT00336674

Phase 2 Completed 110 enrolled Melbourne Health
RandomizedParallel-groupTriple-blindPrevention

Summary

In people with type 1 diabetes the beta cells of the pancreas no longer make insulin because the body's immune system has attacked and destroyed the beta cells. It is thought that exposure of the mucous membranes to insulin may cause act like a vaccine effect whereby protective immune cells are stimulated and these then counteract the "bad" immune cells that damage the beta cells. This study aims to determine if intranasal insulin can protect beta cells and stop progression to diabetes in individuals who are at risk.

Timeline

Start
2006-12
Primary completion
2019-11-13
Completion
2019-11-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic 440 iu Intranasal